The MET receptor is expressed in approximately 40–50% of NSCLC tumors; high levels of receptor expression, as well as high MET gene copy number are independent prognostic factors of poor outcome in patients with resected NSCLC (22, 23). This evidence concerns the gene MET and non-small cell lung carcinoma.